Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

Inclusion Criteria: * Patients between 18 and 65 years old * Crohn's disease patients * Inflammatory activity confirmed by imaging techniques (colonoscopy or magnetic resonance imaging (MRI)) * Refractory inflammatory luminal disease (with or without perianal involvement) at any level of the gastrointestinal tract requiring therapy with adalimumab,according to standard clinical practice. * Stable maintenance of any other medication (corticosteroids and / or immunosuppressants and/or 5-aminosalicylic acid (5-ASA)) for the past 4 weeks * Screening tests required for a safe administration of anti tumour necrosis factor (anti-TNF) antibodies will be performed according to standard clinical practice Exclusion Criteria: * Subjects consuming prebiotic supplements (inulin, FOS, galactooligosaccharides (GOS)) in their regular diet. * Antibiotic use within the past 2 months * Previous anti-TNF therapy.